STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
crizotinib Sensitive: C4 – Case Studies
|
crizotinib Sensitive: C4 – Case Studies
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ABT 263 Sensitive: D – Preclinical
|
ABT 263 Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
cobimetinib Sensitive: D – Preclinical
|
cobimetinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ceritinib + PF-05212384 Sensitive: D – Preclinical
|
ceritinib + PF-05212384 Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ensartinib Sensitive: D – Preclinical
|
ensartinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
cobimetinib + ceritinib Sensitive: D – Preclinical
|
cobimetinib + ceritinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
ceritinib Sensitive: D – Preclinical
|
ceritinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
brigatinib Sensitive: D – Preclinical
|
brigatinib Sensitive: D – Preclinical
|
STRN-ALK rearrangement
|
Mesothelioma
|
STRN-ALK rearrangement
|
Mesothelioma
|
cisplatin + gemcitabine Resistant: D – Preclinical
|
cisplatin + gemcitabine Resistant: D – Preclinical
|